International Flavors & Fragrances (IFF) Stock Price & How to Invest

International Flavors & Fragrances makes the taste, scent and functional ingredients that go into other companies' products: flavor systems for beverages, snacks and dairy, fine and consumer fragrances, enzymes, cultures, probiotics and soy proteins. The company traces to 1833 and reached its current scale through the 2018 Frutarom acquisition and the February 2021 Reverse Morris Trust merger with DuPont's Nutrition & Biosciences division, a roughly $26 billion combination that made IFF one of the four global ingredient houses alongside Givaudan, dsm-firmenich and Symrise. As of the second quarter of 2026 it reports three continuing segments, Taste (~$688 million of quarterly sales), Health & Biosciences (~$601 million) and Scent (~$665 million), after moving the Food Ingredients and Soy Crush businesses into discontinued operations.

The investment picture is a portfolio being cut down deliberately. The DuPont merger left IFF with well over $10 billion of debt and leverage above 4x, and management has worked it down through a run of disposals: Microbial Control to Lanxess, Savory Solutions to Kerry, Cosmetic Ingredients to Clariant for ~$810 million, Pharma Solutions to Roquette at an enterprise value of up to ~$2.85 billion in May 2025, and the German nitrocellulose business for ~$161 million. Net debt stood at ~$5.2 billion at June 30, 2026 and leverage at ~2.5x credit adjusted EBITDA, comfortably inside the 3.75x covenant. The Food Ingredients sale to CVC, expected to close by the end of the second quarter of 2027, is meant to fund more than $1 billion of further debt reduction and a $2.5 billion buyback, which leaves the question of whether the smaller, higher-margin remainder can grow enough to justify what the market already pays for it.

The CVC transaction is not expected to close until the end of the second quarter of 2027 and remains subject to regulatory approvals, so both the $2.0 billion post-close buyback and the promised debt paydown are contingent rather than banked. Stranded costs are the near-term execution problem: roughly $3.2 billion of sales and ~$520 million of EBITDA leave the company, and the overhead that supported them has to be removed for the stated margin uplift to be real. GAAP earnings remain thin relative to the market value, with trailing net income of ~$277 million against a ~$21.5 billion capitalization, because ~$948 million of annual depreciation and amortization and a string of disposal charges sit between EBITDA and reported profit. Goodwill of ~$8.1 billion and intangibles of ~$3.7 billion still make up a large share of a ~$14.0 billion equity base that already absorbed multi-billion-dollar impairments in 2022 and 2023, so further writedowns are possible if end markets soften. Antitrust exposure is also open: European Commission, UK CMA and Swiss inspections of fragrance pricing continue, and while IFF settled the U.S. civil class actions for roughly $43 million in provisions, an Israeli class action over a Frutarom-era bonus was certified in September 2025 with a rehearing motion still pending.

18 analysts publish price targets on IFF, averaging $95.66 against a $84.18 price as of August 2026, or +13.6%. The published targets run from $76.00 to $105.00, a moderate spread, and the ratings split 14 buy, 6 hold, 0 sell. Over the last six months there have been 9 raises and 2 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full IFF forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on International Flavors & Fragrances. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. The Food Ingredients sale and the capital return attached to it. On May 29, 2026 IFF agreed to sell its Food Ingredients business to funds advised by CVC Capital Partners at an enterprise value of about $4.3 billion, retaining a ~10% minority stake and expecting ~$3.8 billion of net cash proceeds. The most optimistic published target, $105.00, assumes this works close to its best case.

The case against. The CVC transaction is not expected to close until the end of the second quarter of 2027 and remains subject to regulatory approvals, so both the $2.0 billion post-close buyback and the promised debt paydown are contingent rather than banked. The most pessimistic target, $76.00, is roughly what IFF is worth if this bites instead.

Read the full bull and bear case on IFF, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see International Flavors & Fragrances's investor relations page or your broker.

• Revenue (TTM, all businesses): ~$10.8B
• FY 2026 sales guidance (continuing operations): ~$7.4B to ~$7.6B
• Q2 2026 adjusted operating EBITDA margin: ~20.9%
• Adjusted EPS ex-amortization (first half 2026): ~$1.74
• Net debt and leverage: ~$5.2B, ~2.5x credit adjusted EBITDA
• Market cap and forward P/E: ~$21.5B, ~25x

The two revenue figures are not a contradiction: trailing revenue of ~$10.8 billion covers the whole company, while 2026 guidance of ~$7.4 billion to ~$7.6 billion covers only the three segments IFF is keeping, since Food Ingredients and the Soy Crush businesses moved to discontinued operations in the second quarter. Trailing GAAP EPS of ~$1.08 puts the shares near 78 times earnings, a number distorted by amortization and disposal charges, which is why the forward multiple of roughly 25 times is the one most analysts quote. Enterprise value of about $26.6 billion against ~$2.06 billion of trailing credit adjusted EBITDA works out near 13 times, while Food Ingredients is being sold at roughly 8 times its own EBITDA.

Other names that sit close to IFF: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get IFF exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so IFF sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where IFF fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

IFF has finished the deleveraging that defined it since 2021 and is now selling its lowest-margin segment to fund buybacks, so the debate has shifted from balance sheet repair to whether the remaining Taste, Scent and Health & Biosciences business deserves a higher multiple.

Whether IFF is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is IFF a buy or a sell?, and where the stock could go from here in the IFF stock forecast.

For income investors, whether IFF pays a dividend and how the payout looks is covered in does IFF pay a dividend? And to weigh IFF against a peer, read the full side-by-side comparisons: IFF vs SXT and IFF vs GLW.